BioAtla (BCAB) Income from Continuing Operations (2020 - 2026)
BioAtla's (BCAB) quarterly Income from Continuing Operations came in at 9291000.0 in Q1 2026, up 46.91% year-on-year from 6324080.5 in Q1 2025, and down 1.19% quarter-over-quarter from 9182000.0 in Q4 2025.
BioAtla (BCAB) Income from Continuing Operations (2020 - 2026) Analysis & Trends
BioAtla's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 9291000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 46.91% year-over-year to 9291000.0 in Q1 2026; TTM through Mar 2026 was 60023000.0, a 11.48% increase from a year earlier, with the FY2025 full-year figure at 174394000.0, down 0.67% from the prior year.
- Income from Continuing Operations retreated to 9291000.0 in Q1 2026 per BCAB's latest filing, from 9182000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9182000.0 in Q4 2025 and bottomed at 2759502000.0 in Q3 2022.
- The 5-year median for Income from Continuing Operations is 26273000.0 (2025), against an average of 219234764.71.
- Across the five-year window, Income from Continuing Operations slumped 11403.2% in 2022 and soared 98.76% in 2023, its largest moves.
- Year by year, Income from Continuing Operations stood at 27913000.0 in 2022, then increased by 2.65% to 27172000.0 in 2023, then jumped by 42.24% to 15695000.0 in 2024, then soared by 41.5% to 9182000.0 in 2025, then declined by 1.19% to 9291000.0 in 2026.
- Per Business Quant, the three latest BCAB Income from Continuing Operations figures stand at 9291000.0 (Q1 2026), 9182000.0 (Q4 2025), and 15277000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | BioAtla | 5.74 Mn | 5.74 Mn | - | -9.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.29 Mn |
| Dec 31, 2025 | -9.18 Mn |
| Sep 30, 2025 | -15.28 Mn |
| Jun 30, 2025 | -26.27 Mn |
| Mar 31, 2025 | -17.50 Mn |
| Dec 31, 2024 | -15.70 Mn |
| Sep 30, 2024 | -11.85 Mn |
| Jun 30, 2024 | -22.77 Mn |
| Mar 31, 2024 | -472.87 Mn |
| Dec 31, 2023 | -27.17 Mn |
| Sep 30, 2023 | -34.13 Mn |
| Jun 30, 2023 | -133.99 Mn |
| Mar 31, 2023 | -27.86 Mn |
| Dec 31, 2022 | -27.91 Mn |
| Sep 30, 2022 | -2.76 Bn |
| Jun 30, 2022 | -91.08 Mn |
| Mar 31, 2022 | -24.64 Mn |
| Dec 31, 2021 | -23.76 Mn |
| Sep 30, 2021 | -23.99 Mn |
| Jun 30, 2021 | -45.58 Mn |